Supplementary Table 1: **Clinical, histopathological and genetic characteristics of the patient tumours used for secretome production.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Sample No.** | **Age of patient at diagnosis****(years)** | **Sex** | **LBD (mm)** | **UH (mm)** | **CBI** | **EOE** | **Cell type** | **Loops** | **Mitotic count/****40 HPF** | **Chr3 status** | **Mets risk** |
| S116-12 | 59 | F | 15.7 | 5.2 | N | N | SPIN | Y | 7 | L | HR¥ |
| S140-12 | 58 | M | 17.6 | 11 | N | Y | MIX | N | 5 | L | HR\* |
| S147-12 | 61 | M | 16.3 | 8.6 | N | N | MIX | Y | 5 | N | LR\* |
| S175-12 | 64 | F | 17.4 | 6.5 | N | N | SPIN | N | 3 | N | LR |
| S194-12 | 41 | M | 12.7 | 11.6 | N | N | MIX | N | 3 | N | LR |
| S195-12 | 77 | F | 14.7 | 5.7 | N | N | EPI | N | 7 | L | HR\* |
| S197-12 | 71 | F | 13.6 | 8 | N | N | MIX | Y | 6 | L | HR |
| S220-12 | 80 | F | 18.2 | 12.5 | N | Y | MIX | N | 1 | L | HR |
| S221-12 | 51 | M | 16.2 | 14.8 | Y | N | SPIN | Y | 4 | N | LR |
| S223-12 | 67 | M | 18.7 | 12.2 | Y | N | MIX | N | 2 | L | HR\* |
| S265-12 | 76 | F | 15.4 | 7.8 | N | N | SPIN | N | 7 | L | HR |
| S281-12 | 71 | M | 13 | 5.9 | N | Y | MIX | N | 4 | L | HR\* |
| S282-12 | 65 | M | 19.2 | 16.8 | Y | N | MIX | Y | 1 | L | HR |
| S285-12 | 77 | F | 15.2 | 8.9 | N | N | MIX | N | 4 | L | HR |

*LBD: largest basal diameter; UH: tumour thickness; F: Female; M: Male; CBI: ciliary body involvement; EOE: extraocular extension; cell type: spindle, mixed, epithelioid; HPF: high power field; HR: high risk; LR: low risk; Chromosome 3 status: N-normal, L-loss, G-gain; \*indicates death from metastatic disease;* $¥$ *indicates death from other causes.*